First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
| Title: | First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial. |
|---|---|
| Authors: | Okuma, Yusuke, Kubota, Kaoru, Shimokawa, Mototsugu, Hashimoto, Kana, Kawashima, Yosuke, Sakamoto, Tomohiro, Wakui, Hiroshi, Murakami, Shuji, Okishio, Kyoichi, Hayashihara, Kenji, Ohe, Yuichiro |
| Source: | JAMA Oncology; Jan2024, Vol. 10 Issue 1, p43-51, 9p |
| Database: | Complementary Index |
| ISSN: | 23742437 |
|---|---|
| DOI: | 10.1001/jamaoncol.2023.5013 |
| Published in: | JAMA Oncology |
| Language: | English |